- About us
- Clinical trials
- News & Publications
The design of SO-C101 enables its fusion to monoclonal antibodies, allowing it to precisely target tumor antigens, tumor stroma or T cells. As a result, SOTIO is developing SO-C108, an immunocytokine fusing SO-C101 to pembrolizumab in order to directly target T cells. This fusion allows for spatial colocalization of an IL-15 superagonist with an anti-PD-1 checkpoint inhibitor, to best enhance their synergistic modes of action and potentially improve outcomes. SO-C108 is one of the first IL-15/PD-1 targeting immunocytokines.
Preclinical data indicate that SO-C108 administration is more efficacious than the administration of SO-C101 and pembrolizumab in combination.